

# Reducing Cardiovascular Events in Your Patients with Type 2 Diabetes Mellitus

Scott Urquhart, PA-C, DFAAPA; Davida Kruger, MSN, APRN-BC, BC-ADM

## CONTINUING MEDICAL EDUCATION

### LEARNING OBJECTIVES

After reading this article, the clinician should be able to:

1. Describe why glycemic control alone is insufficient to prevent long-term adverse cardiovascular outcomes
2. Characterize the cardiovascular complications observed in type 2 diabetes mellitus
3. Describe the results of cardiovascular outcome trials of glucose-lowering medications for type 2 diabetes mellitus, focusing on medications shown to reduce cardiovascular events
4. Individualize glucose-lowering medication shown to reduce cardiovascular events in patients with type 2 diabetes mellitus and with or without established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease

### TARGET AUDIENCE

Family physicians and clinicians who wish to gain increased knowledge and greater competency regarding primary care management of diabetes mellitus.

### DISCLOSURES

As a continuing medical education provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Primary Care Education Consortium (PCEC) requires any individual in a position to influence educational content to disclose any financial interest or other personal relationship with any commercial interest. This includes any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed by the faculty.

Davida Kruger discloses that she is on the advisory board for Abbott, Dexcom, Eli Lilly, Intarcia, Janssen, Merck, Novo Nordisk, and Sanofi Aventis. She is on the speakers' bureau for Abbott, AstraZeneca, BI/Lilly, Dexcom, Eli Lilly, Insulet, Janssen, Novo Nordisk, and Valeritas. Ms. Kruger performs grant and research support to the Henry Ford Health System for Abbott, Dexcom, Helmsley Foundation, Lexicon, and Novo Nordisk. She also owns stock in Dexcom.

Scott Urquhart discloses that he is on the speakers' bureau for AstraZeneca and Novo Nordisk and serves on the advisory board for AstraZeneca, Novo Nordisk and Sanofi.

Gregory Scott, PharmD, RPh, editorial support, discloses he has no real or apparent conflicts of interests to report. Additional PCEC staff report no conflicts of interest.

### SPONSORSHIP

This activity is sponsored by Primary Care Education Consortium, in collaboration with the Primary Care Metabolic Group.

### ACCREDITATION

The Primary Care Education Consortium is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### CREDIT DESIGNATION

AMA PRA Category 1 – Primary Care Education Consortium designates this activity for a maximum of 1.0 AMA PRA Category 1 credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME is available November 1, 2019 to October 31, 2020.

### METHOD OF PARTICIPATION

**PHYSICIANS:** To receive CME credit, please read the journal article and, on completion, go to [www.pceconsortium.org/CVEEvents](http://www.pceconsortium.org/CVEEvents) to complete the online post-test and receive your certificate of credit.

**PHYSICIAN ASSISTANTS:** AAPA accepts certificates of participation of educational activities certified for AMA PRA Category 1 Credit<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society.

**NURSE PRACTITIONERS AND REGISTERED NURSES:** The American Nurses Credentialing Center accepts AMA PRA Category 1 Credit<sup>™</sup> issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for recertification.

### SUPPORTER

This article supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

### FACULTY

Davida Kruger, MSN, APRN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Health System, Division of Endocrinology, Diabetes and Bone Disease, Detroit, MI; Scott Urquhart, PA-C, DFAAPA, Past President, American Society of Endocrine PAs (ASEPA), Adjunct Clinical Professor, PA Program, James Madison University, Diabetes and Thyroid Associates, Fredericksburg, VA

### ACKNOWLEDGEMENT

Editorial support was provided by Gregory Scott, PharmD, RPh, at the Primary Care Education Consortium (PCEC).

## CASE SCENARIO

A 67-year-old woman was diagnosed with type 2 diabetes mellitus (T2DM) 7 years ago. At the time, her glycated hemoglobin (A1c) was 8.7% and body mass index (BMI) 34.6 kg/m<sup>2</sup>. After 10 months of lifestyle management, her A1c was 8.2% and her BMI 32.8 kg/m<sup>2</sup>. Metformin was added and titrated to 1 g twice daily. Currently, her A1c is 7.6%, BMI 33.1 kg/m<sup>2</sup>, blood pressure 138/94 mm Hg, and low-density lipoprotein cholesterol (LDL-C) 86 mg/dL. Her estimated glomerular filtration rate is 74 mL/min/1.73 m<sup>2</sup> with no evidence of albuminuria. She was diagnosed with 75% obstruction of the left anterior descending coronary artery 1.5 years ago. In addition to metformin, her current medications are hydrochlorothiazide 25 mg, rosuvastatin 20 mg, both once daily, isosorbide dinitrate 20 mg three times daily, and nitroglycerin prn.

What change would you make to her treatment plan for T2DM?

## CARDIOVASCULAR RISK IN TYPE 2 DIABETES MELLITUS

As shown by the Framingham Heart Study 4 decades ago, T2DM is an independent cardiovascular (CV) risk factor, conferring a greater risk of CV disease in men and women with diabetes mellitus compared with those without diabetes mellitus (relative risk [RR], 2.1 and 2.6, respectively).<sup>1</sup> The risk is especially high in men and women with diabetes mellitus versus without diabetes mellitus for intermittent claudication (RR, 3.6 and 5.7, respectively) and heart failure (HF) (RR, 2.1 and 4.6, respectively). In fact, peripheral arterial disease is the most common initial presentation of CV disease in persons with T2DM (hazard ratio, 2.98).<sup>2</sup> Generally, the risk of cardiovascular events increases with the duration of T2DM. For example, the risk of both myocardial infarction (MI) and HF in persons with T2DM for 20 or more years is approximately twice the risk compared with persons with T2DM for less than 5 years.<sup>3</sup>

As shown by the United Kingdom Prospective Diabetes Study, glycemic lowering reduces CV events. For every 1% reduction of the A1c, the incidence of HF is reduced 16%, MI 14%, and stroke 12%.<sup>4</sup> Lower extremity amputation or fatal peripheral vascular disease is reduced 43% for every 1% reduction of the A1c. These findings are an important reminder of 2 key points to consider when managing patients with T2DM. (1) A treat-to-target approach to achieve and maintain glycemic targets is important.<sup>5</sup> (2) Reducing the blood glucose is important, but a key treatment objective is to reduce microvascular and macrovascular disease.

### Other cardiovascular risk factors

In addition to T2DM, there are other independent modifiable risk factors for CV disease, including smoking, obesity, hyperlipidemia, and hypertension. It is, therefore, critical

that all major risk factors for CV disease be identified and appropriately managed. The American Diabetes Association (ADA) does not recommend routine screening for coronary heart disease in asymptomatic patients provided that identified CV risk factors are appropriately managed.<sup>6</sup> Screening should be considered in patients with atypical cardiac symptoms, such as unexplained dyspnea or chest discomfort, if there are signs or symptoms of associated vascular disease, or if abnormalities on the electrocardiogram are noted.<sup>6</sup>

In the case scenario above, further treatment of the patient's body weight, blood pressure, and elevated LDL-C is needed to achieve recommended targets and reduce CV risk.<sup>7-9</sup> An angiotensin converting enzyme inhibitor or angiotensin receptor blocker should be considered as a component of antihypertensive therapy and for kidney protection. Other components of comprehensive management of patients with T2DM include antiplatelet therapy, physical activity, regular examination of eyes, mouth/teeth, skin, feet, and kidney function, as well as diabetes distress and overall quality of life.

### Communication about cardiovascular risk

Communicating with patients with diabetes mellitus about CV risk is important since the majority are not aware that CV disease is the leading cause of death in patients with T2DM as shown by the "For Your Sweet Heart" survey.<sup>10</sup> Moreover, the survey showed that half of patients with T2DM do not realize that they are at an increased risk for CV disease and related macrovascular events. Becoming aware of this association would prompt 88% to modify their diet and 81% to talk with their health care provider. At the minimum, it is suggested that discussion with the patient with T2DM about CV risk address the following 3 questions<sup>11</sup>:

- What is a heart attack?
- What is my risk of having a heart attack?
- How can I reduce my risk?

The discussion might include the consequences of CV disease, including not only mortality, but reduced functioning and quality of life, as well as pain. It also may be helpful to compare the patient's risk for a CV event with a person of average risk using the American College of Cardiology ASCVD Risk Estimator (<https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/>). Similarly, comparing the patient's A1c, blood pressure, and cholesterol with recommended targets can help the patient focus on the path to improved CV health, beginning with a shared decision making process to develop a treatment plan.

## CARDIOVASCULAR OUTCOME TRIALS

### US Food and Drug Administration 2008 guidance

Approximately 20 years following publication of the

**TABLE Medications for type 2 diabetes mellitus showing cardiovascular benefit**

Medication	CVOT(s)	Use/prevention	MACE <sup>a</sup>	HF benefit	Renal benefit
GLP-1 Receptor Agonists					
Albiglutide <sup>14</sup>	HARMONY	2°	✓		
Dulaglutide <sup>15,16</sup>	REWIND	1° & 2°	✓		✓
Liraglutide <sup>17,18</sup>	LEADER	1° & 2°	✓		✓
Semaglutide <sup>19</sup>	SUSTAIN 6 <sup>b</sup>	1° & 2°	✓		✓
Sodium Glucose Cotransporter-2 Inhibitors					
Canagliflozin <sup>20,21</sup>	CANVAS/-R, CREDENCE	1° & 2°	✓	✓	✓
Dapagliflozin <sup>22,23</sup>	DECLARE-TIMI 58	1° & 2°		✓	✓
Empagliflozin <sup>24-26</sup>	EMPA-REG OUTCOME	2°	✓	✓	✓

**Abbreviations:** CVOT, cardiovascular outcome trial; HF, heart failure; MACE, major adverse cardiovascular event.

<sup>a</sup>Composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke

<sup>b</sup>Injectable route of administration

Framingham Heart Study showing an increased risk of CV disease in patients with diabetes mellitus, a meta-analysis of 42 randomized controlled trials was published suggesting that rosiglitazone increased the risk of MI in patients with T2DM.<sup>12</sup> Further investigation several years later allayed these concerns, but in the interim, the US Food and Drug Administration (FDA) issued a guidance in 2008 requiring industry sponsors to demonstrate in a clinical trial that a new medication for T2DM is not associated with an unacceptable increase in CV risk compared to placebo as part of standard care in patients at increased risk of a CV event.<sup>13</sup> The guidance applies to all medications for T2DM developed since 2008, including the dipeptidyl peptidase-4 inhibitors (DPP-4is), glucagon-like peptide-1 receptor agonists (GLP-1RAs) (except exenatide twice-daily, since it was approved prior to issuance of the FDA guidance), and sodium glucose cotransporter-2 inhibitors (SGLT-2is).

The primary endpoint of a CV outcome trial (CVOT) is the incidence of a major adverse CV event (MACE), which is a composite of CV death, nonfatal MI, and nonfatal stroke. Most CVOTs also investigate other CV events, eg, HF and kidney function. The trials should be long enough to obtain enough events and to provide data on longer-term CV risk. They should include patients with T2DM at higher risk of CV events, eg, advanced disease, advanced age, or renal impairment.

The FDA guidance specifies that a finding of noninferiority, ie, safety comparable to placebo, is demonstrated if the upper limit of the two-sided 95% confidence interval (CI) for the estimated risk ratio is less than 1.3. If noninferiority is demonstrated, further investigation to assess CV risk reduction is allowed. A risk ratio less than 1 indicates superiority, demonstrating that the new medication reduces CV risk compared to placebo as part of standard care.

### Overview of cardiovascular outcome trials

One or more CVOT has been completed for all 4 DPP-4is (alogliptin, linagliptin, saxagliptin, sitagliptin), 6 GLP-1RAs (albiglutide, dulaglutide, exenatide once-weekly, liraglutide, lixisenatide, injectable and oral semaglutide), and 3 SGLT-2is (canagliflozin, dapagliflozin, empagliflozin). The VERTIS-CV trial for ertugliflozin is ongoing. Most of the trials have included patients at high risk of CV disease (1° prevention) as well as patients with established CV disease (2° prevention). All completed CVOTs have demonstrated the new medication for T2DM is noninferior to placebo as part of standard care, thereby providing reassurance that it poses no increased CV risk.


In addition, superiority, ie, significant reduction in CV risk, has been demonstrated for the primary endpoint (MACE) for the GLP-1RAs albiglutide, dulaglutide, liraglutide, and injectable semaglutide and the SGLT-2is canagliflozin and empagliflozin (TABLE).<sup>14-26</sup> Furthermore, the GLP-1RAs dulaglutide, liraglutide, and semaglutide have shown a reduction in kidney events, while empagliflozin, canagliflozin, and dapagliflozin have shown a reduction in kidney events, as well as HF events, in CVOTs.

It is also worth noting that the safety of insulin glargine U-100 has been shown to be noninferior to standard care for MACE in a head-to-head trial.<sup>27</sup> The safety of degludec was compared with glargine U-100 in a head-to-head trial showing degludec to be noninferior to glargine U-100 for MACE.<sup>28</sup> Finally, in its review of the new drug application for glargine U-300, the FDA concluded that there is no safety concern with glargine U-300 compared with glargine U-100.<sup>29</sup>

### PATIENT-CENTRIC APPROACH TO DIABETES CARE

A key principle of the ADA Standards of Medical Care in

**FIGURE** Treatment of patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease or chronic kidney disease who do not achieve glycemic control with first-line therapy of metformin and comprehensive lifestyle management<sup>31</sup>



**Abbreviations:** ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; CVOTs, cardiovascular outcome trials; DPP-4i, dipeptidyl peptidase-4 inhibitor; FDA, US Food and Drug Administration; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA<sub>1c</sub>, hemoglobin A1c; HF, heart failure; SGLT-2i, sodium glucose cotransporter-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.

<sup>a</sup>Proven CVD benefit means it has label indication of reducing CVD events. For GLP-1 RA, liraglutide is FDA approved to reduce the risk of MACE in adults with type 2 diabetes and established CVD; liraglutide and dulaglutide showed superiority for MACE outcomes in large CVOTs; semaglutide showed superiority for MACE outcomes in a safety CVOT. These results were primarily in patients with known ASCVD although there was consistent benefit in the dulaglutide trial in patients with and without established ASCVD. For SGLT-2i, evidence modestly stronger for empagliflozin > canagliflozin.

<sup>b</sup>Be aware that SGLT-2i vary by region and individual agent with regard to indicated level of eGFR for initiation and continued use.

<sup>c</sup>Empagliflozin, canagliflozin, and dapagliflozin have shown reduction in HF and reduction in CKD progression in CV outcome trials.

<sup>d</sup>Degludec or glargine U-100 have demonstrated CV safety.

<sup>e</sup>Low dose may be better tolerated though less well studied for CVD effects.

<sup>f</sup>Choose later generation sulfonylurea with lower risk of hypoglycemia.

**Source:** American Diabetes Association. Standards of medical care in diabetes-2019, American Diabetes Association, 2019. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.

Diabetes – 2019 is for the provision of patient-centered diabetes care, ie, care that is respectful of and responsive to individual patient preferences, needs, and values, and that ensures that patient values guide all clinical decisions.<sup>30</sup> Medication-

specific factors are an important consideration as well and include effectiveness in glycemic lowering, adverse events (particularly hypoglycemia and weight change), route of administration, cost, and contraindications/warnings.

According to the ADA, the following classes of medications are recommended for a patient *without established* atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) who does not achieve adequate glycemic control with metformin and lifestyle management in the following situations<sup>31</sup>:

- Compelling need to minimize hypoglycemia: DPP-4i, GLP-1RA, SGLT-2i, thiazolidinedione
- Compelling need to minimize weight gain or promote weight loss: GLP-1RA with good efficacy for weight loss or SGLT-2i

• Cost is a major issue: sulfonylurea or thiazolidinedione

For patients *with established* ASCVD or CKD who do not achieve adequate glycemic control with metformin and lifestyle management, the ADA now provides specific recommendations for combination glucose-lowering therapy (FIGURE, previous page).<sup>31</sup> These diabetes medications do not replace the need for other therapy for ASCVD, HF, or CKD as recommended in current guidelines.

#### Patients where established atherosclerotic cardiovascular disease predominates

For a patient where established ASCVD predominates, the addition of either a GLP-1RA or SGLT-2i with proven CV disease benefit as reflected in FDA-approved labeling is recommended. Based on the results of the CVOTs, the FDA-approved indication for the following medications has been updated to include the following:

- Canagliflozin: to reduce the risk of MACE in adults with T2DM and established CV disease and to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with T2DM and diabetic nephropathy with albuminuria >300 mg/d<sup>32</sup>
- Empagliflozin: to reduce the risk of CV death in adult patients with T2DM and established CV disease<sup>33</sup>
- Liraglutide: to reduce the risk of MACE in adults with T2DM and established CV disease<sup>34</sup>

An SGLT-2i should not be initiated in a patient with an estimated glomerular filtration rate <45 mL/min/1.73 m<sup>2</sup>. For GLP-1RAs, the strongest evidence is for liraglutide, dulaglutide, and semaglutide and for SGLT-2is, empagliflozin over canagliflozin. It should be noted that this hierarchy was determined by the ADA Standards of Care panel based on available evidence, but that the CVOTs were not head-to-head comparisons of the new medication with active treatment.

#### Patients where established heart failure or chronic kidney disease predominates

For a patient where HF or CKD predominates, an SGLT-2i

with evidence of reducing HF and/or CKD progression is preferred provided that the eGFR is  $\geq 45$  mL/min/1.73 m<sup>2</sup>.<sup>31</sup> Therefore, canagliflozin, dapagliflozin, or empagliflozin are recommended for patients with established HF or CKD.<sup>20-26</sup> Note that the FDA-approved indication for canagliflozin has been expanded to include a benefit in patients with CKD based upon the results of the CREDENCE trial.<sup>21</sup> Similarly, the FDA-approved indication for dapagliflozin has been expanded to include a benefit in patients with heart failure. If an SGLT-2i is not tolerated, the addition of a GLP-1RA with proven CV benefit is recommended. For a patient with CKD, dulaglutide, liraglutide, or semaglutide would be preferred due to their demonstrated benefits in slowing progression of kidney disease.<sup>15,17-19</sup>

#### CASE SCENARIO (SUMMARY)

This patient's inadequate glycemic control with metformin and lifestyle management indicates the need for treatment intensification. Since she has established ASCVD, the use of a GLP-1RA or SGLT-2i with proven CV benefit is recommended. Of these, the use of a medication with an approved ASCVD-related indication would be preferred, ie, canagliflozin, empagliflozin, and liraglutide.

If the patient had established HF or CKD, an SGLT-2i with proven CV benefit is recommended, ie, canagliflozin, dapagliflozin, and empagliflozin. Additional therapy to address comorbidities as recommended in current guidelines also would be necessary.

Finally, while it may be preferable to use medications approved by the FDA for reducing CV risk in patients with T2DM and established CV disease, insurance coverage may necessitate consideration of other medications in the same class. In this case, those shown to provide a CV benefit may be preferred. ●

#### REFERENCES

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. *JAMA*. 1979;241(19):2035-2038.
2. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. *Lancet Diabetes Endocrinol*. 2015;3(2):105-113.
3. Larsson SC, Wallin A, Hakansson N, Stackelberg O, Back M, Wolk A. Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. *Int J Cardiol*. 2018;262:66-70.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321(7258):405-412.
5. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019. *Diabetes Care*. 2019;42(Suppl 1):S61-S70.
6. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. *Diabetes Care*. 2019;42(Suppl 1):S103-S123.
7. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardi-

- ology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *J Am Coll Cardiol*. 2014;63(25 Pt B):2985-3023.
8. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507-520.
  9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Circulation*. 2018;139(25):e1082-e1143.
  10. Perreault L, Boardman MK, Pak J. The Association Between Type 2 Diabetes and Cardiovascular Disease: The "For Your SweetHeart" Survey. *Adv Ther*. 2019;36(3):746-755.
  11. Roach P, Marrero D. A critical dialogue: communicating with type 2 diabetes patients about cardiovascular risk. *Vasc Health Risk Manag*. 2005;1(4):301-307.
  12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*. 2007;356(24):2457-2471.
  13. US Food and Drug Administration. Guidance for Industry. Diabetes Mellitus- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf>. Accessed February 6, 2018.
  14. Hernandez AF, Green JB, Jamhamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 2018;392(10157):1519-1529.
  15. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394(10193):121-130.
  16. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. *Lancet*. 2019;394(10193):131-138.
  17. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311-322.
  18. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med*. 2017;377(9):839-848.
  19. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375(19):1834-1844.
  20. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377(7):644-657.
  21. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380(24):2295-2306.
  22. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019;380(4):347-357.
  23. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. *Lancet Diabetes Endocrinol*. 2019;doi: 10.1016/S2213-8587(19)30180-9.
  24. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-2128.
  25. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*. 2016;375(4):323-334.
  26. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2017;5(8):610-621.
  27. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367(4):319-328.
  28. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med*. 2017;377(8):723-732.
  29. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Application number: 206538Orig1s000. Medical review(s). [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2015/206538Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000MedR.pdf). Accessed May 17, 2017.
  30. American Diabetes Association. Standards of Medical Care in Diabetes-2019. *Diabetes Care*. 2019;42(Suppl 1):S1-S193.
  31. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. *Diabetes Care*. 2019;42(Suppl 1):S90-S102.
  32. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; November 2018.
  33. Jardiance [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2019.
  34. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; June 2019.